Laura Kühlewein

Dr. Laura Kühlewein

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
MFM. Dominik Fischer
M. Dominik Fischer
Stylianos MichalakisStylianos Michalakis
Stylianos Michalakis
BWBarbara Wilhelm
Barbara Wilhelm
DZDitta Zobor
Ditta Zobor
RMRegine Muehlfriedel
Regine Muehlfriedel
BWBernd Wissinger
Bernd Wissinger
Achromatopsia is an inherited disease that affects cone photoreceptors in the retina. Individuals with achromatopsia demonstrate a total lack of function of all 3 types of cones in the retina.1 Achromatopsia is clinically characterized by day blindness (hemeralopia), glare, poor visual acuity, involuntary oscillatory movement of the eyes (nystagmus), and failure to discriminate chromatic contrasts (achromatopsia). In contrast to common forms of color blindness, in which alterations in the opsin genes affect spectral sensitivity only, patients with achromatopsia lack any cone response from birth. Consequently, patients do not report progression of symptoms, and the disease was initially thought to be nonprogressive. Previous studies,2-4 however, established structural alterations and foveal lesions that emerge with age and are consistent with a slowly progressive degeneration and loss of cone photoreceptor cells in patients with achromatopsia. Variants in 6 genes are implicated in achromatopsia, which together likely explain more than 90% of cases.5,6 Most prevalent are pathogenic variants in the 2 genes that encode the α and β subunits of the cone cyclic nucleotide-gated (CNG) channel, CNGA3 (found in approximately 25%-28% of European and US cases) and CNGB3 (50% of cases).7 CNG channels are essential components of the phototransduction process in cone photoreceptors, which enable daylight vision, high spatial and temporal resolution, color discrimination, and stable fixation. No treatment is currently available for achromatopsia, and any procedure that results in improvement of day blindness and visual function is therefore desired.

12 June 2020 in Human Mutation
Verified
Journal Article
Open access
PDF file
NWNicole Weisschuh
Nicole Weisschuh
COCarolin D. Obermaier
Carolin D. Obermaier
FBFlorian Battke
Florian Battke
ABAntje Bernd
Antje Bernd
LKLaura Kuehlewein
Laura Kuehlewein
SKSusanne Kohl
Susanne Kohl
We aimed to unravel the molecular genetic basis of inherited retinal degeneration (IRD) in a comprehensive cohort of patients diagnosed in the largest center for IRD in Germany. A cohort of 2,158 affected patients from 1,785 families diagnosed with IRD was analyzed by targeted next‐generation sequencing (NGS). Patients with single‐gene disorders (i.e., choroideremia and retinoschisis) were analyzed by Sanger sequencing and multiplex ligation‐dependent probe amplification. Our study cohort accounts for ∼7% of the estimated 30,000 patients with IRD in Germany, thereby providing representative data for both the prevalence of IRDs and the mutation spectrum of IRD genes for the population in Germany. We achieved a molecular diagnostic rate of 35–95%, depending on the clinical entities, with a high detection rate for achromatopsia, retinoschisis, and choroideremia, and a low detection rate for central areolar choroidal dystrophy and macular dystrophy. A total of 1,161 distinct variants were identified, including 501 novel variants, reaffirming the known vast genetic heterogeneity of IRD in a mainly outbred European population. This study demonstrates the clinical utility of panel‐based NGS in a large and highly heterogeneous cohort from an outbred population and for the first time gives a comprehensive representation of the genetic landscape of IRDs in Germany. The data are valuable and crucial for the scientific community and healthcare providers, but also for the pharmaceutical industry in the progressing field of personalized medicine and gene therapy.

18 May 2021 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
FRFelix F Reichel
Felix F Reichel
Stylianos MichalakisStylianos Michalakis
Stylianos Michalakis
BWBarbara Wilhelm
Barbara Wilhelm
DZDitta Zobor
Ditta Zobor
RMRegine Muehlfriedel
Regine Muehlfriedel
DFDominik Fischer
Dominik Fischer
Aims To determine long-term safety and efficacy outcomes of a subretinal gene therapy for CNGA3-associated achromatopsia. We present data from an open-label, nonrandomised controlled trial (NCT02610582). Methods Details of the study design have been previously described. Briefly, nine patients were treated in three escalating dose groups with subretinal AAV8.CNGA3 gene therapy between November 2015 and October 2016. After the first year, patients were seen on a yearly basis. Safety assessment constituted the primary endpoint. On a secondary level, multiple functional tests were carried out to determine efficacy of the therapy. Results No adverse or serious adverse events deemed related to the study drug occurred after year 1. Safety of the therapy, as the primary endpoint of this trial, can, therefore, be confirmed. The functional benefits that were noted in the treated eye at year 1 were persistent throughout the following visits at years 2 and 3. While functional improvement in the treated eye reached statistical significance for some secondary endpoints, for most endpoints, this was not the case when the treated eye was compared with the untreated fellow eye. Conclusion The results demonstrate a very good safety profile of the therapy even at the highest dose administered. The small sample size limits the statistical power of efficacy analyses. However, trial results inform on the most promising design and endpoints for future clinical trials. Such trials have to determine whether treatment of younger patients results in greater functional gains by avoiding amblyopia as a potential limiting factor.

Verified
Journal Article
Open access
PDF file
LKLaura Kühlewein
Laura Kühlewein
DZDitta Zobor
Ditta Zobor
KSKatarina Stingl
Katarina Stingl
MKMelanie Kempf
Melanie Kempf
FNFadi Nasser
Fadi Nasser
SKSusanne Kohl
Susanne Kohl
In this retrospective, longitudinal, observational cohort study, we investigated the phenotypic and genotypic features of retinitis pigmentosa associated with variants in the PDE6B gene. Patients underwent clinical examination and genetic testing at a single tertiary referral center, including best-corrected visual acuity (BCVA), kinetic visual field (VF), full-field electroretinography, full-field stimulus threshold, spectral domain optical coherence tomography, and fundus autofluorescence imaging. The genetic testing comprised candidate gene sequencing, inherited retinal disease gene panel sequencing, whole-genome sequencing, and testing for familial variants by Sanger sequencing. Twenty-four patients with mutations in PDE6B from 21 families were included in the study (mean age at the first visit: 32.1 ± 13.5 years). The majority of variants were putative splicing defects (8/23) and missense (7/23) mutations. Seventy-nine percent (38/48) of eyes had no visual acuity impairment at the first visit. Visual acuity impairment was mild in 4% (2/48), moderate in 13% (6/48), and severe in 4% (2/48). BCVA was symmetrical in the right and left eyes. The kinetic VF measurements were highly symmetrical in the right and left eyes, as was the horizontal ellipsoid zone (EZ) width. Regarding the genetic findings, 43% of the PDE6B variants found in our patients were novel. Thus, this study contributed substantially to the PDE6B mutation spectrum. The visual acuity impairment was mild in 83% of eyes, providing a window of opportunity for investigational new drugs. The EZ width was reduced in all patients and was highly symmetric between the eyes, making it a promising outcome measure. We expect these findings to have implications on the design of future PDE6B-related retinitis pigmentosa (RP) clinical trials.

1 November 2019 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
KSKrunoslav T. Stingl
Krunoslav T. Stingl
LKLaura Kuehlewein
Laura Kuehlewein
NWNicole Weisschuh
Nicole Weisschuh
SBSaskia Biskup
Saskia Biskup
FCFrans P. M. Cremers
Frans P. M. Cremers
KSKatarina Stingl
Katarina Stingl
Purpose: Mutations in the CRB1 gene cause early-onset retinal degeneration (EORD). Clinical disease progression markers, such as visual fields or electrophysiology, are not reliably measurable in most patients to follow the retinal function in patients with CRB1-mutations. Methods: Ten patients (five females, five males; age 22–56 years) with EORD caused by CRB1 mutations were examined in a cross-sectional manner using best corrected visual acuity (BCVA), perimetry, full-field and multifocal electroretinography, full-field stimulus threshold (FST), and pupillography to red and blue light. Disease duration was defined as the difference between the age at the first symptoms to the age at examination in years. Results: BCVA was quantifiable in six patients and ranged from light perception to 20/50. The visual field was measurable only in three patients who had the shortest disease duration. Full-field and multifocal electroretinography were not measurable in any patient. FST to blue and red light were measurable in all patients except the one with the longest disease duration; the thresholds ranged from −16.7 to 1.5 dB for red light and from −40.2 to 2.5 dB for blue light (0 dB = 0.01 cd.s/m2) and showed correlations with disease duration (r = 0.87 for blue, r = 0.65 for red, r = 0.8 for blue–red difference). The maximal relative pupil constriction amplitude (MRA) showed low or no correlations with disease duration (r = −0.55 for blue, r = −0.3 for red light); the blue–red difference in the post-illumination pupil responses (PIPR) showed no correlation with disease duration (r = −0.05). Compared to healthy eyes, the MRA to red and blue light was significantly decreased (P < 0.001) and the blue–red PIPR difference was significantly increased (P = 0.003). Conclusions: FST features a valid clinical marker in late-stage early-onset retinitis pigmentosa caused by CRB1 mutations correlating with disease duration. This indicates the potential as a progression marker of disease. The pupil responses to full-field chromatic stimuli show significant differences from the normal population: the remaining responses, although reduced, indicate a partially preserved inner retinal function despite severe photoreceptor dysfunction. Translational Relevance: The functional measurements presented in this study present a valid clinical progression marker in late-stage early onset retinitis pigmentosa caused by biallelic CRB1 mutations. Additionally, they can be used as outcome measures for safety and efficacy in clinical therapy trials.

11 November 2020 in Genes
Verified
Journal Article
Open access
PDF file
JDJulia Doll
Julia Doll
BVBarbara Vona
Barbara Vona
LSLinda Schnapp
Linda Schnapp
FRFranz Rüschendorf
Franz Rüschendorf
Imran KhanImran Khan
Imran Khan
THThomas Haaf
Thomas Haaf
The current molecular genetic diagnostic rates for hereditary hearing loss (HL) vary considerably according to the population background. Pakistan and other countries with high rates of consanguineous marriages have served as a unique resource for studying rare and novel forms of recessive HL. A combined exome sequencing, bioinformatics analysis, and gene mapping approach for 21 consanguineous Pakistani families revealed 13 pathogenic or likely pathogenic variants in the genes GJB2, MYO7A, FGF3, CDC14A, SLITRK6, CDH23, and MYO15A, with an overall resolve rate of 61.9%. GJB2 and MYO7A were the most frequently involved genes in this cohort. All the identified variants were either homozygous or compound heterozygous, with two of them not previously described in the literature (15.4%). Overall, seven missense variants (53.8%), three nonsense variants (23.1%), two frameshift variants (15.4%), and one splice-site variant (7.7%) were observed. Syndromic HL was identified in five (23.8%) of the 21 families studied. This study reflects the extreme genetic heterogeneity observed in HL and expands the spectrum of variants in deafness-associated genes.